ARCELLX INC (ACLX) Stock News

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Mentions: GILD

(ACLX) - Analyzing Arcellx's Short Interest

Arcellx Stock Earns 82 Relative Strength Rating

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Mentions: CPRX ADMA EXEL

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

Mentions: LGND GILD JNJ

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcellx (NASDAQ:ACLX) just reported results for the second quarter of 2024.Arce...

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024

ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.

Mentions: MNMD BEAM JNJ GILD

Arcellx Stock Earns Relative Strength Rating Upgrade

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

Mentions: ADMA HALO UTHR

7 Biotech Stocks to Put on Your Breakthrough Radar

Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.

Mentions: NVO ABBV CRSP BBIO ...

ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcellx (NASDAQ:ACLX) just reported results for the first quarter of 2024.Arcel...